The persons depicted are models used for illustrative purposes only.

BEXSERO is the #1 MenB vaccine in doses sold in the US based on private and public (VFC) total MenB sales data from 2015- 2023¹. More than 100 million doses of BEXSERO have been distributed worldwide since 2015². BEXSERO is approved in more than 50 countries including Canada, Australia, and much of Europe³.
BEXSERO is the #1 MenB vaccine in doses sold in the US based on private and public (VFC) total MenB sales data from 2015- 2023¹. More than 100 million doses of BEXSERO have been distributed worldwide since 2015². BEXSERO is approved in more than 50 countries including Canada, Australia, and much of Europe³.

Order Now

See the Data for Demonstrated Breadth of Immune Response of Diverse MenB Strains

See the Data for Demonstrated Breadth of Immune Response of Diverse MenB Strains

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Doctor Discussion

How do I counsel patients about meningitis B (MenB)?

Our quick guide can help you get started.

Be Prepared

Warning Icon

Don't disregard the threat of MenB

Although meningococcal disease is uncommon, it can progress quickly. In fact, it can lead to death.4

Get the Facts

Stopwatch Icon

Complete your patients' MenB series using a vaccine with nearly a decade of experience

BEXSERO has a 2-dose schedule for every appropriate patient who follows the 6-month interval.5

More Dosing Info

Antigenic Components

Explore the 4 antigens

BEXSERO is the only MenB vaccine that combines 4 different antigenic components.5,6

Learn More

Shopping Cart Icon

Place an order today

Stock up on BEXSERO with GSKDirect.

Order Now

Newspaper Icon

Get the latest product updates

Connect with a Sales Representative.

Connect Now

Watch a real MenB survivor story

  • Video transcript

    On-Screen Text:

     

    Kim is a meningococcal disease Advocate. She is not a healthcare provider. This is her story in her own words. Kim was compensated by GSK for her participation in this program. This is one person’s experience. Other people’s experiences with meningococcal disease may be different. Vaccination may not protect all recipients.

     

    Kim:

     

    I’d say a few days before Spring Break, Lindsey called and wasn’t feeling real well. They diagnosed her with a virus, and we decided that she would come home and enjoy some good quality family time with Alan (her dad) and I and her older sister, Jordan. So, Alan and I were working in the yard and Lindsey had been laying down for a bit, and I thought, “You know, I should probably go check on her.” She was sleeping, and when I reached down to touch her skin, she was extremely warm. So, I reached down, and I put the thermometer under her arm, and—and it read 104. We immediately rushed her to the ER. I remember meningitis being mentioned multiple times. We just knew that she felt awful—awful. I remember pulling meningitis up on the internet, and I’ll never forget reading the description—that she could have organ damage. Pictures that showed this horrible petechiae rash with people missing limbs. And then reading that it could potentially take my daughter’s life. That’s scary. Eventually, Lindsey’s physician came in and confirmed that Lindsey had a diagnosis of meningococcal septicemia, serogroup B. Lindsey was in the hospital for 14 days, and it was probably the longest 14 days of my life, and we were so incredibly blessed that she recovered. If I would have known that there was a way to help prevent what happened to Lindsey, I would have taken it in a heartbeat. I want healthcare professionals to give moms and dads the information that we need to help protect our children.

     

    On-Screen Text:

     

    Adolescents/young adults need vaccines to help protect against the 5 vaccine-preventable serogroups for meningitis—Men A, B, C, W, & Y. Vaccination may not protect all recipients.

     

    Kim:

     

    Please educate us about the types of vaccines needed to help protect against the five most common types of meningitis. So many people who experience meningitis, their children don’t make it. They don’t get that second chance.

     

    On-Screen Text:

     

    GSK LOGO

     

    Trademarks are owned by or licensed to the GSK group of companies.

     

    ©2023 GSK or licensor.

     

    BEXVID230048 November 2023

     

    Produced in USA.

Vaccination may not protect all recipients.

 

fHbp=factor H binding protein; NadA=Neisserial adhesin A; NHBA=Neisserial Heparin Binding Antigen; OMV=Outer Membrane Vesicles.

INDICATION & IMPORTANT SAFETY INFO
INDICATION

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

  • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO
  • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO